Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription

Articles published in
    January 2024
  1. WU J, Wu Y, Chen S, Guo Q, et al
    PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/beta-catenin signalling pathway.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
    >> Share

  2. LIU H, Deng S, Yao X, Liu Y, et al
    Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer.
    Oncogene. 2024 Jan 15. doi: 10.1038/s41388-024-02940.
    >> Share

  3. WU CJ, Pan KF, Chen JQ, Tao Y-, et al
    Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment.
    Oncogene. 2024 Jan 4. doi: 10.1038/s41388-023-02918.
    >> Share

    December 2023
  4. YU X, Zhao P, Luo Q, Wu X, et al
    RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-kappaB activation and ovarian cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02910.
    >> Share

    November 2023
  5. AKINJIYAN FA, Ibitoye Z, Zhao P, Shriver LP, et al
    DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
    Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02884.
    >> Share

  6. CALLENS C, Rodrigues M, Briaux A, Frouin E, et al
    Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
    Oncogene. 2023;42:3556-3563.
    >> Share

    October 2023
  7. TAO YP, Zhu HY, Shi QY, Wang CX, et al
    S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway.
    Oncogene. 2023 Oct 12. doi: 10.1038/s41388-023-02853.
    >> Share

    September 2023
  8. PETTITT SJ, Shao N, Zatreanu D, Frankum J, et al
    A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-?11q splice variant.
    Oncogene. 2023;42:2701-2709.
    >> Share

    August 2023
  9. RAY U, Thirusangu P, Jin L, Xiao Y, et al
    PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.
    Oncogene. 2023 Aug 7. doi: 10.1038/s41388-023-02785.
    >> Share

    July 2023
  10. HEINZL N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, et al
    Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
    Oncogene. 2023 Jul 4. doi: 10.1038/s41388-023-02758.
    >> Share

    June 2023
  11. LI Y, Chen Z, Peng J, Yuan C, et al
    The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
    Oncogene. 2023 Jun 30. doi: 10.1038/s41388-023-02763.
    >> Share

    April 2023
  12. JIANG Y, Song L, Lin Y, Nowialis P, et al
    ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02679.
    >> Share

    March 2023
  13. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
    Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02629.
    >> Share

  14. CHEN K, Yuan X, Wang S, Zheng F, et al
    MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650.
    >> Share

    December 2022
  15. LI G, Yi X, Du S, Gong L, et al
    Tumour-derived exosomal piR-25783 promotes omental metastasis of ovarian carcinoma by inducing the fibroblast to myofibroblast transition.
    Oncogene. 2022 Dec 8. doi: 10.1038/s41388-022-02560.
    >> Share

    November 2022
  16. HE Y, OuYang Z, Liu W, Chen Y, et al
    TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing.
    Oncogene. 2022 Nov 11. pii: 10.1038/s41388-022-02539.
    >> Share

    October 2022
  17. HUANG TT, Burkett SS, Tandon M, Yamamoto TM, et al
    Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
    Oncogene. 2022 Oct 12. pii: 10.1038/s41388-022-02491.
    >> Share

    July 2022
  18. SHEN Z, Gu L, Liu Y, Wang L, et al
    PLAA suppresses ovarian cancer metastasis via METTL3-mediated m(6)A modification of TRPC3 mRNA.
    Oncogene. 2022 Jul 22. pii: 10.1038/s41388-022-02411.
    >> Share

    June 2022
  19. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    Correction to: An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2022 Jun 6. pii: 10.1038/s41388-022-02356.
    >> Share

    April 2022
  20. ZHU S, Zhang C, Cao D, Bai J, et al
    Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
    Oncogene. 2022 Apr 25. pii: 10.1038/s41388-022-02277.
    >> Share

    February 2022
  21. KWON J, Choi H, Ware AD, Morillo BC, et al
    USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model.
    Oncogene. 2022 Feb 16. pii: 10.1038/s41388-022-02224.
    >> Share

  22. LIN L, Shi K, Zhou S, Cai MC, et al
    SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
    Oncogene. 2022 Feb 5. pii: 10.1038/s41388-022-02210.
    >> Share

    January 2022
  23. LI J, Zheng C, Wang M, Umano AD, et al
    ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer.
    Oncogene. 2022 Jan 18. pii: 10.1038/s41388-021-02149.
    >> Share

  24. JAMES NE, Woodman M, Ribeiro JR
    Prognostic immunologic signatures in epithelial ovarian cancer.
    Oncogene. 2022 Jan 14. pii: 10.1038/s41388-022-02181.
    >> Share

  25. KAN T, Zhang S, Zhou S, Zhang Y, et al
    Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.
    Oncogene. 2022 Jan 7. pii: 10.1038/s41388-021-02139.
    >> Share

    November 2021
  26. YIN L, Zeng Y, Zeng R, Chen Y, et al
    Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
    Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02117.
    >> Share

  27. BOUDHRAA Z, Zaoui K, Fleury H, Cahuzac M, et al
    NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer.
    Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02082.
    >> Share

    September 2021
  28. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
    Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Oncogene. 2021 Sep 23. pii: 10.1038/s41388-021-02020.
    >> Share

    August 2021
  29. LI H, Qi Z, Niu Y, Yang Y, et al
    FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer.
    Oncogene. 2021 Aug 6. pii: 10.1038/s41388-021-01957.
    >> Share

    July 2021
  30. LI Y, Fei H, Lin Q, Liang F, et al
    ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
    Oncogene. 2021 Jul 1. pii: 10.1038/s41388-021-01913.
    >> Share

    June 2021
  31. ZHANG J, Guan W, Xu X, Wang F, et al
    A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01891.
    >> Share

  32. WU Y, Guo Q, Ju X, Hu Z, et al
    HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.
    Oncogene. 2021 Jun 19. pii: 10.1038/s41388-021-01884.
    >> Share

  33. WU YH, Huang YF, Chang TH, Chen CC, et al
    COL11A1 activates cancer-associated fibroblasts by modulating TGF-beta3 through the NF-kappaB/IGFBP2 axis in ovarian cancer cells.
    Oncogene. 2021 Jun 11. pii: 10.1038/s41388-021-01865.
    >> Share

    May 2021
  34. TAN J, Zheng X, Li M, Ye F, et al
    C/EBPbeta promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    Oncogene. 2021 May 8. pii: 10.1038/s41388-021-01788.
    >> Share

    April 2021
  35. LINDZEN M, Ghosh S, Noronha A, Drago D, et al
    Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53.
    Oncogene. 2021 Apr 30. pii: 10.1038/s41388-021-01784.
    >> Share

  36. ALI R, Alblihy A, Miligy IM, Alabdullah ML, et al
    Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    Oncogene. 2021;40:2496-2508.
    >> Share

    January 2021
  37. YOSHIDA K, Yokoi A, Sugiyama M, Oda S, et al
    Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01595.
    >> Share

  38. NOH K, Bach DH, Choi HJ, Kim MS, et al
    The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.
    Oncogene. 2021;40:384-395.
    >> Share

    October 2020
  39. ZHANG Q, Zhou W, Yu S, Ju Y, et al
    Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation.
    Oncogene. 2020 Oct 20. pii: 10.1038/s41388-020-01516.
    >> Share

  40. RANZUGLIA V, Lorenzon I, Pellarin I, Sonego M, et al
    Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
    Oncogene. 2020;39:6370-6386.
    >> Share

    September 2020
  41. XU Z, Li X, Li H, Nie C, et al
    Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01482.
    >> Share

  42. MEHNER C, Miller E, Hockla A, Coban M, et al
    Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
    Oncogene. 2020 Sep 14. pii: 10.1038/s41388-020-01451.
    >> Share

    May 2020
  43. LI J, Alvero AB, Nuti S, Tedja R, et al
    CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.
    Oncogene. 2020;39:3965-3979.
    >> Share

    March 2020
  44. TAMURA R, Yoshihara K, Nakaoka H, Yachida N, et al
    XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
    Oncogene. 2020 Mar 2. pii: 10.1038/s41388-020-1237.
    >> Share

  45. HAYASHI T, Sano K, Aburatani H, Yaegashi N, et al
    Initialization of epithelial cells by tumor cells in a metastatic microenvironment.
    Oncogene. 2020;39:2638-2640.
    >> Share

    November 2019
  46. CLUZET V, Devillers MM, Petit F, Chauvin S, et al
    Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.
    Oncogene. 2019 Nov 19. pii: 10.1038/s41388-019-1109.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016